Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Epistemonikos ID: 1e8f81610f812116d0fb2f4a6744753b5c09be4d
First added on: May 09, 2024